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Abstract
Hepatitis B is a worldwide healthcare problem, especially in developing areas. 
An estimated one-third of the global population has been infected with this virus; 
approximately 350 million people are lifelong carriers, and only 2% spontane-
ously seroconvert annually. Hepatitis B virus (HBV) belongs to the hepadnavirus 
family of enveloped DNA viruses containing a partially double-stranded genome 
of 3182 ± 3221 bp depending on the genotype that encodes four overlapping 
open reading frames. HBV is classified into eight genotypes (A–H) that are 
geographically dispersed. Genotype A is predominant in North America, Western 
Europe, and Africa; genotypes B and C in Asia; genotype D in Southern Europe, 
Africa, and India; genotype E in West Africa; genotype F in Central and South 
America and Alaska; genotype G has been found in the United States, France, and 
Germany; and genotype H in Central America. Genotypes A, B, C, and D pre-
dominate in the United States, while the other genotypes are less common. Further 
detailed analysis of these HBsAg variants would provide further understanding of 
the antigenic structure of HBV.
Keywords: genotypes, subtypes, surface antigen, hydrophilic region,  
HBsAg variants
1. Introduction
A report by Blumberg in 1965 led to the discovery of hepatitis B surface antigen 
(HBsAg) which is also known as Australian antigen and its related antibody which 
is hepatitis B surface antibody or HBsAb [1]. After a gap of 5 years, in 1970, another 
scientist, Dane, visualized the hepatitis B (HBV). Since that time, a significant 
development has been made about the epidemiology, virology, natural history, and 
the treatment of this hepatotropic virus. It is the smallest of the DNA viruses that 
infect man and cause acute hepatitis of varying severity. It is an extremely resistant 
strain capable of withstanding extreme temperatures and humidity. It can survive 
when stored for 25 years at −20°C, for 24 months at −80°C, for 6 months at room 
temperatures, and for 7 days at 44°C [2].
Hepatitis B is a global healthcare problem, especially found in developing 
countries. As per an estimate, one third of the world population has been infected 
with this virus which is around 350 million people are enduring carriers and only 
2% of them are spontaneously seroconvert yearly [3]. Many current vaccination 
programs seem to be promising in the effort to reduce the incidence of this disease 
[4]. HBV is transmitted through hematological and sexual means. The consequence 
of this infection is a complex viral-host interaction which results in either as an 
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acute disease with symptoms or an asymptomatic disease. Patients may develop 
an immunity to HBV or it may enter a chronic carrier state (Figure 1). The later 
consequences of this infection are cirrhosis and then development of hepatocel-
lular carcinoma (HCC) [5]. Hepatitis B virus (HBV) belongs to the hepadnavirus 
family of enveloped DNA viruses containing a partially double-stranded genome 
of 3182 ± 3221 bp depending on the genotype which encodes four overlapping and 
open reading frames which are as follows:
• S for the surface or envelope gene encoding the pre-S1, pre-S2, and the S 
protein
• C for the core gene, encoding for the core nucleocapsid protein and the “e” 
antigen
• X for the X gene encoding the X protein
• P for the polymerase gene encoding, a large protein promoting priming, RNA-
dependent and DNA-dependent DNA polymerase, and RNase H activities
The genome is read in all three reading frames, and viral regulatory elements 
are all within coding regions which introduce constraints on the ability of the 
virus to accept mutations and remain viable [6]. Nevertheless, heterogeneity 
among the strains of HBV circulating globally is 10%-fold greater than that in the 
majority of DNA viral genomes. This is explained, at least partially, by the fact 
that hepadnavirus replication takes place via an RNA intermediate, and reverse 
transcriptase is known to have a high error rate 16. A nucleotide exchange rate 
of between 0–1 and 0–7 per year [7] has been estimated for the HBV [8] and 
woodchuck hepatitis virus (WHV) [9]; genomes, respectively, which is similar 
Figure 1. 
HBV genome showing S for the surface or envelope gene encoding the pre-S1, pre-S2, and the S protein.
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to the most slowly evolving gene of retroviruses, the gag gene, and one to two 
orders of magnitude lower than the mutation rates previously calculated for the 
positive- and negative-strand RNA viruses [10]. The virus persists in 2–10% of 
adult patients and approximately 90% of infected infants leading to chronic liver 
disease. In highly endemic areas, infection is predominantly acquired during the 
perinatal neonatal period or by horizontal transmission in the first few years of 
life [10–11] which results in a high prevalence of long-term HBV carriers with a 
low average age at infection [12], the virus has a long time span in which to evolve 
within its host.
1.1 Natural history
Acute infection with HBV in adulthood is rarely associated with the develop-
ment of potentially fatal fulminant liver failure. Chronic infection, whether 
acquired in childhood or in adulthood, is associated with progressive liver disease, 
risk of cirrhosis, liver failure, and HCC and rarely with extrahepatic manifestations. 
Chronic HBV infection is characterized by four distinct phases: immune tolerance, 
immune clearance, inactive carrier state, and reactivation [13]. The immune toler-
ance phase is characterized by detectable HBeAg, high levels of HBV DNA (>105 
copies/ml), and normal ALT levels. The immune clearance phase, also called CHB, 
is characterized by detectable or undetectable HBeAg, undetectable or detectable 
anti-HBe antibodies, lower or fluctuating levels of HBV DNA, high or fluctuating 
ALT levels, and active inflammation as seen on liver biopsy. The inactive HBsAg 
carrier state is characterized by detectable HBsAg, undetectable HBeAg, detectable 
anti-HBe antibodies, low levels of HBV DNA (<104 copies/ml), and normal ALT 
levels. Later in the carrier phase, HBsAg may become undetectable, and anti-HBs 
antibodies may appear [13], although reactivation can occur in inactive HBV carri-
ers (Figure 2).
Figure 2. 
Different stages of HBV infection. https: //www.123rf.com/photo_83543016_stock-illustration-liver-disease-
progression-in-hepatitis-c-virus-infection-3d-illustration.html.
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2. The surface gene and variants
HBV is classified into eight genotypes (A–H) that are geographically dispersed. 
Genotype A is predominant in North America, Western Europe, and Africa; geno-
types B and C in Asia; genotype D in Southern Europe, Africa, and India; genotype 
E in West Africa; genotype F in Central and South America and Alaska; genotype 
G has been found in the United States, France, and Germany; and genotype H in 
Central America. Genotypes A, B, C, and D predominate in the United States, 
while the other genotypes are less common. 31 Genotype B is associated with less 
active disease, slower progression, and lower incidence of hepatocellular carcinoma 
(HCC) than genotype C. Genotypes A and B generally respond better to treatment 
with interferon than do genotypes C and D. No relation between HBV genotypes 
and response to nucleos(t)ide analogue-based therapies has been demonstrated 31.
Originally, four genotypic groups of HBV (A–D) were defined, based on an 
inter-genotypic divergence score of 8 ± 5–10 ± 0% between 18 complete genomes, 
as compared to a score of 1 ± 1–2 ± 7% between isolates within the same genotype 
[14]. This genotypic classification was extended to six genotypes (A–F) by phyloge-
netic analysis of 122 surface antigen (HBsAg) genes [15]. The genotypic groups are 
geographically arranged [16] with genotypes B and C confined to Asia, while geno-
type A predominates in Northern Europe giving way to genotype D as one moves 
toward the Mediterranean region. Genotype E is mainly found in parts of East, 
Central, and West Africa, and genotype F is only found in the New World and the 
Pacific which is also home to the Cq—subgroup of genotype C [17]. Two subgroups 
of genotype A, subgroups A and A, were found in approximately equal amounts in 
an urban population from South Africa together with 10% of genotype D [17].
In the recent advances in molecular diagnostic techniques, it was found that HBV 
envelop is made of host-derived bilayer of phospholipids encoded by S gene. c1.
3. The surface gene variants
The mutation in HBV depends on the high rate of replication of this virus which 
in turn depends on RNA- dependent DNA polymerase. In highly variant individu-
als, the mutation of genome can be up to 1010 per day. Whereas most of the variants 
produced are defective, some of them can cause infection or reason for treatment 
failure.
3.1 HBsAg variants
In the structure of virus, the coat of the outer surface is made up of hepatitis B 
surface proteins which are made in larger amounts than needed by the virus to its 
reproduction process. The excess amount of these surface proteins clusters together 
into some spherical units of size between 17 and 25 nm of diameter, and sometimes 
it also forms rods of different lengths. It is found that in some studied cases, these 
units condense as a core particle to produce a whole and infectious virus unit that 
passes into the blood stream and can also infect many other healthy liver cells. All 
the different structures like extra spheres, rodlike and also sometimes complete 
viral particles easily move in the blood stream in large amount and can be easily 
detected; only it takes little long time for these protein particles to appear in blood.
The incubation time for this hepatitis B Virus (hepatitis B) can be between 6 and 
25 weeks. It was found that after infection for up to 1 to 6 weeks before symptoms 
start occurring, HBsAg appears. To confirm the presence of hepatitis B infection, 
the positive result for the presence of hepatitis B surface protein (HBsAg) is the 
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available standard test to indicate current infection. If the hepatitis B surface 
protein (HBsAg) remains present for a time of more than 6 months, it is generally 
considered as an indicator for chronic infection.
It is reported that if excess of HBs proteins is produced, it may allow infectious 
hepatitis B virus particles to leak the immune system by mopping some low levels of 
surface antibodies that may be produced by the immune system due to its 145 amino 
acid which is glycine that changes to arginine (G145R) [18].
3.2 Hepatitis B core protein (HBcAg)
The HBc proteins link together to form the hepatitis B core that encapsulates 
HBV DNA and DNA polymerase; this core is in turn encapsulated by HBs proteins.
The core protein (HBc) is not detectable in the bloodstream; however it can be 
detected in the sample of liver cells taken after a liver biopsy.
3.3 HBe protein (HBeAg or “e” antigen)
The Hepatitis B “e” antigen (HBeAg) is a peptide and normally detectable in the 
bloodstream when the hepatitis B virus is actively reproducing; this in turn leads to 
the person being much more infectious and at a greater risk of progression to liver 
disease. The exact function of this nonstructural protein is unknown; however it is 
thought that HBe may be influential in suppressing the immune system response to 
HBV infection. HBeAg is generally detectable at the same time as HBsAg and disap-
pears before HBsAg disappears. The presence of HBeAg in chronic infection is gener-
ally taken to indicate that HBV is actively reproducing and there is a higher probability 
of liver damage. In acute infection HBeAg is generally only transiently present [19].
However mutant strains of HBV exist that replicate without producing HBeAg. 
In many cases infection with these mutant strains is more aggressive than HBe 
producing strains [20].
4. Variants associated with antiviral therapy
Polymerase variants are another class of variants detected during therapy with 
nucleoside analogues which become the reason for drug resistance. The most 
recognized mutation affecting lamivudine drug is due to change in 204 amino acid 
from methionine to valine or isoleucine (M204 V/I) which sometimes occurs with 
another change at 180 amino acid position (L180 M). This change helps in replica-
tion and healthy survival of the mutant.
In HBV-infected patients during liver transplant therapy, antiviral prophylaxis 
is combined with HBIG drug as the polymerase gene and surface gene in HBV have 
the same regions of the genome; although read in a different frame, the mutation 
in one can force the other for it. This could lead to complications in selection of 
mutants for both HBsAg and HBV polymerase [21].
4.1 HBV variants associated with active immunization
Active immunization is the most effective way to control the prominent cause of 
hepatitis, human hepatitis B virus (HBV). The highly antigenic hepatitis B surface 
antigen (HBsAg) is directly related to induce the humoral immune response, which 
on the other hand provides immunity against HBV infection. Neutralizing B cell 
epitopes are believed to be due to changes in position 124 to 147 of HBsAg, defined 
as the “a” determinant [22].
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In recent years, HBV variants with mutations on the “a” determinant have been 
recognized following vaccination. These mutants are proficient in independent 
replication and lead to active infection [23–25]. These mutations have been identi-
fied at various positions on the “a” determinant, the most often identified being the 
glycine-to-arginine change at position 145 (G145R) of HBsAg [25–31].
The most important is that some of the mutants existed before the vaccination 
program is introduced. These include changes of amino acids at positions 126, 129, 
133, and 145 [29, 31]. Some of these are naturally occurring HBsAg variants which 
are transmissible and are able to infect even the vaccinated population [29, 31]. 
HBsAg variants have recently been recognized on the major hydrophilic loop of 
HBsAg (aa 100–160) but outside the conventional “a” determinant [32]. These new 
mutants can occur in both the vaccinated and unvaccinated individuals in a popula-
tion and are not able to be neutralized by the presently available antibodies.
5. HBsAg in liver transplantation
The patients suffering with chronic HBV contagion are having high risk of 
developing cirrhosis and hepatic liver failure and having hepatocellular carcinoma. 
The well-known orthotopic liver transplantation (OLT) procedure is a well-estab-
lished treatment for liver failure and other hepatocellular carcinoma patients. The 
occurrence of HBV infection creates many exceptional issues with patients under-
going orthotopic liver transplantation treatment. The inability to get treatment and 
HBV reinfection occurs in almost 75–80% of persons who undergo OLT treatment. 
Recurrence of HBV infection even after OLT repeatedly followed by aggressive 
clinical treatments and also related with a major decrease in successful graft and the 
rate of patient recovery. In recent times some new antiviral therapies and prophy-
lactic schemes using hepatitis B immune globulin (HBIG) have been established to 
decrease the risk of recurrence of HBV infection in OLT patients.
5.1 Liver transplantation after treatment of HBV infection
There are numerous aims of providing antiviral therapy to patients with cir-
rhosis which is secondary to prolonged HBV infection. The patients who have with 
compensated cirrhosis, they can get antiviral therapy which can inhibit develop-
ment to decompensated cirrhosis and eradicate the possible requirement for OLT 
treatment. The antiviral therapy can effectively decrease the risk of advancement to 
hepatocellular carcinoma.
For patients having decompensated cirrhosis, antiviral therapy can improve liver 
function which can also delay the need for transplantation. If the patient’s condition 
progresses to the point that transplantation is needed, the aim of antiviral therapy is 
to minimize the HBV risk at the time of transplantation, thereby controlling the risk 
of recurrence of HBV infection after OLT.
5.1.1 Major therapies for minimizing HBV infection or recurrence
IFN-α: Before starting treatment with IFN-α, the hazards and uses related to 
IFN-α therapy must be carefully assessed in patients having cirrhosis with chronic 
HBV infections. IFN-α treatment is related with a burst in serum aminotransferases 
in 35–55% of already treated patients. For patients having progressive liver disease, 
IFN-α rehabilitation may increase the hepatic breakdown, so it has to be avoided. 
IFN-α treatment can aggravate cytopenia and additional intensification the risk 
of severe bacterial toxicities. IFN-α treatment can be provided safely by keeping 
7Molecular Variants for HBsAg: Surface and Subtype
DOI: http://dx.doi.org/10.5772/intechopen.85282
close monitoring system for the patients having compensated cirrhosis [33]. Some 
researchers prove that up to 31% of the cirrhotic HBV patients cured using IFN-α-2b 
had showed seroconversion of antibody related to hepatitis B antigen, and they 
lose of measureable HBV DNA, in response rates which are similar to that of the 
non-cirrhotic patients. Various studies had shown that the cirrhotic patients who 
have lost HBeAg show superior up to 10 years of survival rate in comparison to the 
patients who had shown no response to IFN-α therapy [34]. Some of the researchers 
had shown in there research that the rate of incidence of hepatocellular carcinoma 
may be lesser in patients who had received treatment using IFN-α, generally in the 
subcategory of patients who had cleared HBV DNA from their blood serum [35, 36]. 
Generally, the risks related to IFN-α treatment and the occurrence of harmless and 
well-tolerated oral antiviral therapies have reduced the usefulness of IFN-α treat-
ment in patients having cirrhosis. Pegylated IFN-α-2a was newly accepted by the 
US Food and Drug Administration to be used for the treatment of chronic hepatitis 
B. A few related data is presently available showing the use of pegylated IFN-α in 
relation to cirrhotic patients having hepatitis B.
Lamivudine: It is based on nucleoside analogue which is an effective inhibitor of 
HBV DNA replication process. It was one of the first accepted orally administered 
medications to be used for the treatment of patients having chronic HBV infection. 
It has also confirmed an exceptional safety picture in both the compensated and 
uncompensated patients of cirrhosis. In patients suffering from decompensated 
cirrhosis because of HBV infection, lamivudine is shown to be a safe and effec-
tive drug therapy. Previous researches having uncontrolled case studies show the 
conflicted results for lamivudine treatment which was shown to delay advancement 
to death or toward liver transplantation [37, 38]. Liaw et al. [39] stated the results 
related to a large, potential, multicenter randomized trial based on the study of 
651 patients who had chronic hepatitis B, and bridging fibrosis was randomized to 
obtain any of the lamivudine or placebo. The basic points of this research was time 
essential for the disease development, which is also known as hepatic compensa-
tion, hepatocellular carcinoma, spontaneous bacterial peritonitis, variceal bleeding, 
or death associated with liver disease. After they receive a treatment for a period 
of 32.4 months which can range from 0 to 42 months in which a substantially 
larger percentage of patients in the placebo group in contrast to the lamivudine 
group developed disease advancement (17.7% vs. 7.8%; Pp. 001), because of which 
the study was finished early. Moreover, hepatocellular carcinoma arose in a less 
percentage of patients in the lamivudine-treated individual than in the placebo 
group (3.9% vs. 7.4%, Pp .047). The results show that based on lamivudine is more 
effective in reducing the occurrence of hepatic decompensation and hepatocellular 
carcinoma in patients who have chronic HBV infection and also progressive fibrosis 
or cirrhosis. The main aspect reducing the use of lamivudine is that it causes the 
increase of mutations in the YMDD motif of the HBV DNA polymerase gene, which 
develops resistance against lamivudine. YMDD mutations are emerging with a rate 
of ∼20% every year against lamivudine treatment which are related to the return of 
active viral replication [40]. The findings of lamivudine resistance in clinical setting 
vary according to the rigorousness of underlying liver damage. The initial sign 
related to resistance usually occurs as a recoil in the HBV DNA level, lacking any 
other irregular biochemical or clinical results. However, advanced liver failure has 
been defined in connotation with the occurrence of YMDD mutations.
So, patients with cirrhosis need closely observing during their receiving pro-
longed lamivudine therapy.
Adefovir dipivoxil: An oral prodrug of adefovir which is a nucleotide ana-
logue of adenosine monophosphate that inhibits HBV DNA polymerase. Many 
studies show that adefovir has tremendous activity against wild-type as well as 
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lamivudine-resistant HBV strains. Researchers evaluated the safety and efficacy of 
adefovir dipivoxil (10 mg daily) in 128 patients having lamivudine-resistant HBV 
and are waiting for liver transplantation. Treatment for a period of 48 weeks man-
aged to cause an average decrease in HBV DNA titer of 4.1 log10 copies/ml, where as 
in non-detectable HBV DNA (by PCR; lower limit of detection, 400 copies/ml), it 
was in 81% and showed better Child-Pugh score which is up to 92%. Adefovir dipiv-
oxil treatment can generally be accepted very finely with an increase in their serum 
creatinine level up to 10.5 mg/dL from baseline in around 12% of the patients. No 
patient is required to stop adefovir dipivoxil therapy due to nephrotoxicity. The 
survival rate after 48 weeks was 84% which is significantly better than the rate for 
historical control subjects.
Other oral agents: Entecavir a new guanosine nucleoside analogue which was 
recently accepted by the US Food and Drug Administration for the treatment of 
chronic hepatitis B. Although no publication is done, but a huge phase III research 
has proven that HBeAg-positive patients provided with entecavir (0.5 mg daily 
for 48 weeks) showed a mean change in HBV DNA titer of _6.98 log10 copies/ml, 
which was considerably better than that was found with lamivudine [33]. Entecavir 
has also revealed activity against lamivudine- and adefovir dipivoxil-resistant HBV 
strains. Still there are no exact data available on the use of entecavir in patients with 
decompensated cirrhosis or in association with liver transplantation.
6. Conclusion
HBsAg variants with changes outside the “a” identification of these new HBsAg 
variants and their functional analysis may provide further understanding of the 
antigenic structure of HBV; also liver transplantation for hepatitis B is having 
complication of the risk of recurring HBV infection. It significantly reduces the 
rates of graft success and patient survival after transplantation. Effective therapy 
with OLT recipient patients having chronic HBV infection involves management 
of antiviral therapy before OLT to reduce the hepatitis B viral titer at the time of 
transplantation.
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